SLCO1B1*1B/*1B genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC 0-∞ and increased clearance of repaglinide. Moreover, this polymorphism of SLCO1B1 has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics.
/lp/springer-journals/effects-of-slco1b1-polymorphisms-on-the-pharmacokinetics-and-HElGHKK5yl